阻塞性睡眠呼吸暂停的药物治疗研究进展  

Drug Therapy in Obstructive Sleep Apnea Syndrome

作　　者：李胜男 谢亮 童嘉毅[1] LI Shengnan;XIE Liang;TONG Jiayi(Department of Cardiology,Zhongda Hospital of Southeast University,Nanjing 210009,Jiangsu,China;Department of Cardiology,General Hospital of the Eastern Theater of the Chinese People’s Liberation Army,Nanjing 210009,Jiangsu,China)

机构地区：[1]东南大学附属中大医院心内科,江苏南京210009 [2]中国人民解放军东部战区总医院心内科,江苏南京210009

出　　处：《心血管病学进展》2023年第8期748-751,756,共5页Advances in Cardiovascular Diseases

基　　金：江苏省自然科学基金(BK20211167)。

摘　　要：阻塞性睡眠呼吸暂停(OSA)是睡眠呼吸障碍中最常见的一种,其特征是睡眠期间上呼吸道部分或完全塌陷反复发作,可导致严重的神经认知和心血管损害。持续气道正压通气是OSA的一线治疗,可以改善大多数患者的嗜睡、生活质量和血压。但是其对心血管结局事件的预防作用尚存在争议,同时,患者接受持续气道正压通气治疗的依从性较差。因此,目前迫切需要探索新药物疗法来帮助许多不能或者不愿使用当前治疗方案的OSA患者。现对OSA治疗药物的类别、机制以及影响进行综述。Obstructive sleep apnea(OSA)is the most common form of sleep breathing disorder,characterized by recurrent episodes of partial or complete collapse of the upper airway during sleep,which can lead to severe neurocognitive and cardiovascular impairment.Continuous positive airway pressure is generally considered the first-line treatment for OSA and improves drowsiness,quality of life,and blood pressure in most patients.However,the preventive role of continuous positive airway pressure in cardiovascular outcomes is still controversial,and patient compliance with continuous positive airway pressure therapy is poor.Therefore,there is an urgent need to explore new drug therapies to help the many patients with OSA who are unable or unwilling to use current treatment options.The classes,mechanisms and effects of therapeutic agents for OSA are reviewed.

关 键 词：阻塞性睡眠呼吸暂停 药物治疗 乙酰唑胺 螺内酯 钠-葡萄糖共转运蛋白2抑制剂 大麻素类 托莫西汀 

分 类 号：R766[医药卫生—耳鼻咽喉科]